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Abstract
Background: The Global Programme to Eliminate Lymphatic Filariasis has encouraged countries to follow a set of
guidelines to help them assess the need for mass drug administration and evaluate its progress. Papua New Guinea
(PNG) is one of the highest priority countries in the Western Pacific for lymphatic filariasis and the site of extensive
research on lymphatic filariasis and surveys of its prevalence. However, different diagnostic tests have been used
and thresholds for each test are unclear.
Methods: We reviewed the prevalence of lymphatic filariasis reported in 295 surveys conducted in PNG between
1990 and 2014, of which 65 used more than one test. Results from different diagnostics were standardised using a
set of criteria that included a model to predict antigen prevalence from microfilariae prevalence. We mapped the
point location of each of these surveys and categorised their standardised prevalence estimates.
Results: Several predictive models were produced and investigated, including the effect of any mass drug
administration and number of rounds prior to the surveys. One model was chosen based on goodness of fit
parameters and used to predict antigen prevalence for surveys that tested only for microfilariae. Standardised
prevalence values show that 72% of all surveys reported a prevalence above 0.05. High prevalence was situated
on the coastal north, south and island regions, while the central highland area of Papua New Guinea shows
low levels of prevalence.
Conclusions: Our study is the first to provide an explicit predictive relationship between the prevalence values
based on empirical results from antigen and microfilaria tests, taking into account the occurrence of mass drug
administration. This is a crucial step to combine studies to develop risk maps of lymphatic filariasis for programme
planning and evaluation, as shown in the case of Papua New Guinea.
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Background
Lymphatic filariasis (LF) is a mosquito-transmitted dis-
ease caused by a parasitic nematode (predominantly
Wuchereria bancrofti) that can seriously damage lymph-
atic vessels [1]. This frequently leads to cases of acute
and chronic lymphoedema (extreme inflammation of
lower limbs) and hydrocoele (swollen scrotum in men),
potentially resulting in life-long chronic morbidity [2–4].
Unfortunately, these deformities are associated with the
stigma of disfiguration and can lead to social isolation,
economic hardships and mental distress [5].
Since the resolution to implement the Global Programme
to Eliminate Lymphatic Filariasis (GPELF) by the World
Health Assembly [6], the estimated global burden of LF has
significantly decreased by 59% between 2000 and 2013 [7].
Despite this amazing achievement, about 68 million indi-
viduals in the world remain affected [7], with the corre-
sponding DALYs (disability-adjusted life years lost)
estimated at 2.02 million [8]. However, this estimation does
not include disability from cases of mental illness resulting
from stigmatising conditions, which was estimated at 5.09
million DALYs based on 2010 GBD data [5]. These num-
bers are of concern, suggesting that the GPELF must
continue its strategy of annual single-dose mass drug ad-
ministration (MDA) programs [1] to reduce the burden of
lymphatic filariasis in the world.
Noteworthy are the efforts of the Pacific Program to
Eliminate Lymphatic Filariasis (PacELF), a WHO initia-
tive with island countries, territories and communities in
the Western Pacific region, to collaboratively eliminate
the disease from their populations [9]. This elimination
process requires years of documentation, including ini-
tial mapping surveys, transmission assessment surveys
(TAS) to evaluate MDA cessation and post-MDA sur-
veillance for a period of at least 5 years [10]. Despite
these complexities, the PacELF has achieved a measur-
able success towards their 2020 goals [9], with Vanuatu,
Niue, Republic of Marshall Islands, Cook Islands and
Tonga achieving official elimination of the disease [9].
Other countries, however, still face challenges [11]. Un-
fortunately, studies of filariasis in the region have been
patchy and concentrated in only certain countries [12].
This patchy survey effort extends to Papua New
Guinea (PNG), which continues to struggle with the dis-
ease. For instance, original mapping reported PNG as
potentially containing one of the highest prevalence of
lymphatic filariasis in the world [13], but there are in
fact relatively large areas that are non-endemic to filaria-
sis [14]. Although some studies show that filariasis
prevalence has been reduced after MDA implementation
in selected provinces (i.e. Western and Southern High-
lands, West and East Sepik, Madang and New Ireland),
these have been conducted in limited areas and usually
for just a few years [15–19].
One of the most critical challenges in the Western Pa-
cific region is to identify new strategies to scale up MDA
in PNG [20, 21]. Localised MDA implementation for areas
with high endemicity in PNG has been proposed as a
starting strategy [14], which would benefit from reliable
mapping based on more localised information on disease
distribution. However, previous work summarising sur-
veys conducted in the country from 1980 to 2011 exposed
the many challenges of extracting useful information from
unrelated studies [14]. For instance, previous survey
efforts in PNG used different diagnostic techniques to
report their prevalence [14], as new diagnostic techniques
emerged over time [22]. Nevertheless, the large amount of
information obtained in these surveys from PNG can help
us understand the relationship between prevalence esti-
mates obtained by different diagnostic methods.
Diagnostic tests used in PNG generally fall into two
categories:(a) microfilaraemia (Mf) detection through
blood slides and (b) antigen tests through either
point-of-care immunochromatographic test cards (ICT)
or laboratory analysis (Og4C3 ELISA test) [23]. The first
type of diagnostics detects early-stage nematode worms
circulating in the blood stream [23]. In the case of Papua
New Guinea, these microfilariae follow a nocturnal cir-
culating cycle, to match the feeding behaviour of the
main vector in the region, Anopheles mosquitoes [24].
The two other diagnostic tests detect antigen from the
adult worms instead [23]. Efforts to understand the rela-
tionship between these types of diagnostics have been
inconclusive [25, 26] but remain crucial for combining
varying types of diagnostic results to develop risk maps
of LF in the region [26]. Thus, the association between
Mf detection and antigen results remains an important
research question.
Few studies have explored this association, generally
concluding that these two variables lack a predictive re-
lationship that could be used to combine results in stud-
ies [25]. While efforts using logistic regression were
unable to produce a predictive model [25], further ap-
proaches have proposed that a relationship between
these two diagnostic types exists, and it is based on the
distribution of adult worms and their Mf output [26].
These studies suggest that the relationship between Mf
and antigen diagnostics changes with the presence of
MDA deployment [25, 26], as its implementation effect-
ively reduces the number of Mf, but it takes time to kill
off the adult worms which continue to produce antigen
in the bloodstream. This is an important aspect to con-
sider when developing models to describe this relation-
ship from surveys conducted before and after MDA.
To develop a predictive model between LF diagnostics
tests, we re-examined previously reviewed data sum-
marised only at the district level [14] and consolidated
all existing surveys conducted in PNG since 1990. We
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used this first explicit predictive model of its kind to
aggregate empirical results from different diagnostic
tests and refine our knowledge of LF distribution
according to point estimates of survey locations. In this
paper, we examined the attributes of our proposed
model and its practical use to improve the accuracy of
LF risk maps in PNG.
Methods
Survey selection
We reviewed a total of 312 survey results originally sum-
marised by Graves et al. [14]. Each of these surveys con-
ducted a cross-sectional blood survey for LF, surveying
either one or more villages, schools or a main city and
its catchment. These studies used different diagnostic
methods, as described above, covering 80 different dis-
tricts, from 1980 to 2011 [14]. In the current study, we
restricted the surveys to those conducted from 1990 on-
wards, as explained below. In addition, we included an
extra 14 more surveys that were conducted more re-
cently in 2014. We also extracted information on the
number of MDA rounds (i.e. DEC and albendazole) per-
formed prior to each survey.
Prevalence standardisation
We developed a set of criteria to standardise different
diagnostic results from surveys into one chosen type. Fol-
lowing PacELF monitoring strategies [9], we chose to
standardise for antigen prevalence values over Mf detec-
tion, as the former can be used independently of the diur-
nal/nocturnal cycles of microfilariae [23]. As antigen tests
can determine the presence of adult worms and the poten-
tial for ongoing transmission even after MDA programs,
this type of diagnostics is highly appropriate for the pur-
pose of MDA implementation and culmination [23].
To standardise the results in favour of antigen preva-
lence values, we did the following:
1. As the first reported LF prevalence survey in PNG
using an antigen test (i.e. Og4C3 ELISA) was in
1990, all surveys previous to this year were not
included in our study.
2. For surveys reporting prevalence values from either
an ICT or an Og4C3 ELISA test, these values were
considered without further modifications.
3. For surveys reporting values from both Mf counts
and one other antigen test, only values from the
antigen diagnostics were considered for the final
mapping, although these surveys were used to
develop our predictive model (see point 6).
4. For surveys that reported values from both ICT and
Og4C3 ELISA tests together, the average was
calculated.
5. When a combination of all three diagnostics was
used in a survey, only the average of the two
antigen tests was considered.
6. For surveys that reported prevalence value based on
microfilariae detection only, we predicted antigen
values from these based on a predictive model
developed specifically for this study. This process is
described in the following section.
Predicting antigen prevalence values from Mf estimates
We collected prevalence values from surveys that re-
ported both Mf and antigen prevalence results (surveys
in points 3 and 5 above). While the majority of these 65
surveys have been published in the peer-reviewed litera-
ture, some were extracted from PhD theses and others
from unpublished reports by the WHO or by PNG De-
partment of Health. Data from 51 of these surveys were
previously summarised and reported in detail by Graves
et al. [14]. The remaining 14 surveys were recently con-
ducted by authors of this paper in the East and West Se-
pik provinces as part of ongoing clinical trials evaluating
MDA annual dosages. While procedures followed in
these selected surveys varied, they were all performed
according to best practice recommended techniques
with oversight from the relevant funding bodies, aca-
demic institutions and/or publishers.
Considering previous indications that the relationship
between Mf and antigen diagnostics changes with the
presence of MDA [26–28], we began by averaging ICT
and Og4C3 values for surveys that reported more than
one antigen test. We then conducted an ANOVA test be-
tween prevalence values from surveys conducted before
and after any MDA, for both Mf and antigen results separ-
ately. This was performed to test for a significant differ-
ence with the presence/absence of MDA that would
preclude the investigation of our predictive model.
Through regression analyses, we evaluated four differ-
ent models of the potential relationship between tests
that took into consideration a possible MDA interaction.
These models were based on exponential or power func-
tions grounded on observed patterns in the data. We in-
vestigated two types of MDA interaction for each model
explored: (a) presence/absence (δ = 1 for post-MDA) and
(b) number of MDA rounds. We also developed two sets
of considerations in the analyses of these models based
on two possible scenarios:
(A)Differentiated Scenario models: This approach
assumed that a different type of function had to be
applied as a response to the interaction. Thus, the
dataset was categorised into two groups: pre- and
post-MDA surveys. Individual functions were
tested, and the optimum models were determined
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separately for the pre- and post-MDA data (see
Table 1).
(B) Combined Scenario models: This approach assumed
that the function would be similar before and after
MDA, with only changes to some of the parameters
after MDA deployment. For these analyses, the
entire dataset with both pre- and post-MDA cases
was included, and the optimum models were deter-
mined simultaneously for pre- and post-MDA data
(see Table 2).
The parameters for each of these models were esti-
mated using a nonlinear least square method in R soft-
ware version 3.4.4. The models in the Differentiated
Scenario A considered the MDA interaction (either its
presence/absence or the number of rounds) as an indica-
tor, where the parameters were first estimated based on
the pre-MDA data (n = 49), and then, a scaling factor es-
timated in each model was re-estimated based on the
post-MDA data (n = 16). In the case of models in the
Combined Scenario B, the parameters were estimated
from the combined 65 data points but considered the
MDA interaction as an independent variable (i). We
compared the RSE (residual standard error) and the AIC
(Akaike information criterion) for all models to evaluate
their goodness of fit. The AIC value, in particular, was
used to select one optimum model from each scenario.
For our standardisation process, we chose only one of
these two final models to predict antigen prevalence
from Mf-only surveys. This decision was based on which
function (1) provided the best AIC, (2) was more con-
sistent across scenarios and (3) was supported by the
biggest sample size.
Final standardised prevalence estimates were organised
into three prevalence categories, previously suggested by
Graves et al. [14]. These antigen cut-off categories are
based on a practical understanding of MDA implemen-
tation, settings and protocols [14] and included (a) no or
very low prevalence below the threshold for initiating
MDA (< 1%), (b) low prevalence (between 1 and 5%) and
(c) high prevalence (> 5%), in all age groups.
Spatial analysis
Following a thorough geolocation revision for all surveys
included in this study (details described in the Add-
itional file 1: Table S1), we plotted the surveys over a
map of Papua New Guinea delineated with district
boundaries. The standardised LF antigen prevalence for
each survey was displayed and grouped into the three
prevalence categories described above. Surveys were also
distinguished between three time periods: (a) surveys
conducted between 1990 and 1999, (b) surveys con-
ducted between 2000 and 2009 and (c) surveys con-
ducted from 2010 to 2014.
Results
Analysis of surveys
A total of 295 surveys were included in our analysis, of
which 117 were conducted between 1990 and 1999, and
125 were performed between 2000 and 2009. The
remaining 53 took place between 2010 and 2014. The
breakdown of the different diagnostic tests used in these
surveys is described in Fig. 1. From the 295 surveys se-
lected, 138 reported Mf results: 71 had Mf results only
and 65 reported both Mf and antigen tests together (21
with ICT, 32 with Og4C3 and 12 with both) (Fig. 1).
Predictive models
We initially considered 65 surveys’ results with both Mf
and antigen values to develop our model. ANOVA re-
sults showed that there was a significant difference
between surveys conducted pre-MDA (n = 49) and
post-MDA (n = 16; median rounds = 1). The median
Table 1 Comparison of the Differentiated Scenario A models
Scenario A Model
functions
Pre-MDA MDA
interaction
Post-MDA
RSE AIC RSE AIC
1 y = a(1 − e−bx) 0.1187 − 65.86 δ 0.1789 − 6.69
N 0.1991 − 3.27
2 y = a − be−cx 0.1192 − 64.49 δ 0.1603 − 10.20
N 0.1885 − 5.03
3 y = ae−b/x 0.1218 − 63.30 δ 0.2036 − 2.56
N 0.2198 − 0.11
4 y = axb 0.1209 − 64.04 δ 0.1400 − 14.53
N 0.2024 − 2.74
Differentiated Scenario A models evaluated, with their corresponding RSE and
AIC values. The y variable represents the predicted antigen estimates, while
x is the Mf prevalence as the independent variable. δ is the presence of MDA
while N is the rounds of MDA (acting as indicators). Numbers in bold represent
the lowest AIC values for pre- and post-MDA conditions, suggesting the
best-fit models
Table 2 Comparison of the Combined Scenario B models
Scenario B Model
functions
MDA
interaction
Both pre- and post-MDA
RSE AIC
1 y = a(1 − e−(bx + ci)) δ 0.1224 − 83.66
N 0.1279 − 77.91
2 y = a − be−(cx + di) δ 0.1219 − 83.22
N 0.1242 − 80.83
3 y = ae−b/(x + ci) δ 0.1264 − 80.16
N 0.1353 − 79.91
4 y = axb − ci δ 0.1257 − 79.50
N 0.1260 − 70.60
Combined Scenario B models evaluated, with their corresponding RSE and AIC
values. The y variable represents the predicted antigen estimates, while x is
the Mf prevalence as the independent variable. δ is the presence of MDA
while N is the rounds of MDA (represented by the independent variable i). The
number in bold represent the lowest AIC value from all models in this scenario
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values of Mf prevalence were 0.22 and 0.04 for pre- and
post-MDA, respectively (p < 0.001). The median values
of antigen prevalence for pre- and post-MDA were 0.53
and 0.34, respectively (p < 0.01). This interactive effect of
MDA on the relationship between tests validated our
two modelling scenarios described above. Table 1 shows
the results of the four models evaluated under the Dif-
ferentiated Scenario A.
Table 1 shows how in every instance that the number
of MDA rounds was used as an interaction; it resulted in
a less fit model than considering the presence/absence
of any MDA. This suggests that the occurrence of any
MDA plays a greater role in changing the relationship
between Mf and antigen prevalence than the number of
rounds implemented. From the Differentiated Scenario
A, the optimum models were A1 for the pre-MDA data
(AIC = − 65.86) and model A4 for the post-MDA condi-
tion (AIC = − 14.53).
Regression analysis of models A1 and A4 produced
significant parameters for each function (p < 0.0001;
please refer to the Additional file 1: Table S2 for details).
The resulting curves from models A1 and A4 are de-
scribed in Fig. 2. This approach resulted in diverging
functions, where the pre-MDA curve predicted antigen
estimates that reached an asymptote around 0.8 at
higher levels of Mf prevalence (Fig. 2), while the
post-MDA function reached 1 instead. Confirming pre-
dictions at these high Mf values is challenging after
post-MDA conditions, due to the effect that MDA has
in lowering Mf densities. This was the case with our
dataset, where only 16 surveys had post-MDA informa-
tion for both tests, with the highest Mf prevalence re-
ported as 0.257.
Table 2 compares the RSE and AIC values of the four
different models considered under the Combined Sce-
nario B. From this group of models, model B1 was the
optimum one (AIC = − 83.66). Parameters for model B1
were also significant (p < 0.01; please refer to the Add-
itional file 1: Table S3 for details). Figure 3 depicts model
B1 with its two corresponding curves. These two func-
tions are a product of the independent variable (i) chan-
ging from 0 to 1 under pre- and post-MDA conditions,
respectively. In this case, the pre-MDA curve is always
higher than the post-MDA curve, especially at low Mf
levels (Mf < 0.5). This difference decreased as Mf
Fig. 2 Relationship between antigen and Mf prevalence predicted by models A1 (pre-MDA) and A4 (post-MDA). These combined models result
in a “diverging” predictive relationship between diagnostic tests as Mf prevalence increases
Fig. 1 Distribution of diagnostic tests utilised by the surveys included.
Values represent the number of surveys that utilised a specific diagnostic
or combination of diagnostics
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prevalence increased, with both curves converging
around a predicted antigen value of 0.8, similar to model
A1.
We compared the predictions of antigen prevalence
from Mf estimates made by models A1 and B1 and
found that they were closely aligned with each other. Al-
though model A1 predictions were slightly higher than
the model B1 predictions, the difference was within 1%
in all cases (n = 71 Mf-only surveys). Differences in the
predictions between models A4 and B1 were not as
closely aligned, however, with up to a maximum of 4.5%
difference at Mf levels between 0.2 and 0.3 (these differ-
ences are graphically explored in Additional file 1: Figure
S1A and B). The similarities in functions and estimated
predictions between model A1 (n = 49) and model B1 (n
= 65) lead us to believe that the divergent prediction of
model A4 may be a result of the small sample size used
(n = 16), with no Mf values above 0.3 after MDA. Thus,
considering the ample sample size and low AIC value of
model B1 (Fig. 3), we decided to use this converging
model to predict antigen values for Mf-only surveys (n
= 71) as part of our prevalence standardisation process.
In addition, model B1 produced very reliable predictions
at low prevalence levels (< 10%), a critical range for deci-
sions to implement or cease MDA [10]. Final standar-
dised prevalence values for all surveys are summarised
in Fig. 4.
Figure 4 shows that a third of the surveys con-
ducted in PNG reported a prevalence under 0.1, while
less than 4% of surveys reported prevalence higher
than 0.8. A closer look at our three prevalence cat-
egories shows that at least 20% of these surveys re-
ported prevalence estimates below 0.01, while roughly
three fourths of the surveys described high levels of
prevalence, above 0.05 (Fig. 4).
Risk mapping LF distribution in PNG
The spatial locations of surveys in PNG over time show
variation in the general areas where these studies were
conducted during the decades covered in our analysis
Fig. 3 Relationship between antigen and Mf prevalence predicted by model B1. This model suggests a “converging” predictive relationship
between diagnostic tests as Mf prevalence increases
Fig. 4 Distribution of surveys according to their standardised prevalence
values. Seventy-one out of 295 surveys had their prevalence values
predicted using model B1. The three colours shown represent each of
our prevalence categories: blue—no prevalence (< 0.01), orange—low
prevalence (0.01–0.05) and red—high prevalence (> 0.05), with their
respective percentages
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(Fig. 5). The decade between 2000 and 2009 in particular
shows survey efforts spread all throughout the country,
with low to no prevalence detected in the central region
of PNG. Figure 5 is the most detailed standardised risk
map of LF using surveys’ point locations for the entire
country to date.
Discussion
The elimination of lymphatic filariasis in PNG remains a
daunting enterprise that requires coordinated inter-
national support, as well as national commitment and
clear planning. The GPELF has developed a set of guide-
lines, the initial stage of which requires a comprehensive
mapping of LF prevalence in the country. Unfortunately,
efforts to develop this spatial undertaking have been
patchy and non-encompassing. This has led to inaccur-
ate perceptions of the extent of the disease, as well as
misinforming the programme on the true nature of the
challenges ahead. Our study aimed to assess this situ-
ation and provide an improved and detailed account of
the prevalence distribution of this disease in PNG.
Risk mapping usually requires coordinated prevalence
studies with the intent of obtaining a homogenous sur-
vey effort across the country within a singular timeframe
[10]. Prevalence surveys of LF in PNG are heterogeneous
in nature, occurring over a span of 30 years, with local-
ised research sites and varied diagnostic methods. Our
first challenge was to standardise these different diag-
nostic results, by producing a predictive model that
could provide antigen prevalence values from original
Mf estimates. Although a previous study by Cano et al.
suggested that this relationship is not predictive [25],
our data showed that several predictive models could
describe this relationship mathematically and with rea-
sonable precision. We believe that the difference in re-
sults between our study and Cano’s team stems from the
different approaches used. For instance, while the men-
tioned paper focused on logistic regression for predicting
whether an individual was positive or negative [24], we
conducted non-linear analyses on aggregated prevalence
estimates from a set of surveys. Other possible differ-
ences are discussed further below.
Fig. 5 Distribution from surveys conducted: (a) between 1990 and 1999 (triangles), (b) between 2000 and 2009 (circles) and (c) between 2010
and 2014 (crosses). No or very low (< 1%), low (1 to 5%) and high (> 5%) prevalence categories are represented by blue, orange and dark
red, respectively
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Furthermore, other studies have provided evidence
that a relationship between antigen and Mf prevalence
exists [26, 29]. Our study, however, is the first one to ex-
plicitly describe this relationship using empirical data
through two possible types of models. These models dif-
fer mainly on their prediction of antigen values after
MDA implementation. While models A1 and A4 suggest
a diverging effect caused by the MDA interaction at
higher levels of prevalence (Fig. 2), model B1 shows a
converging result after MDA deployment (Fig. 3).
The shape of the converging curves describing the re-
lationship between antigen and Mf prevalence in model
B1 illuminates several aspects of LF biology, transmis-
sion and diagnostic performance. Firstly, as suggested in
previous studies [26], our model depicts a non-linear re-
lationship between diagnostic tests (Fig. 1). However,
model B1 shows a curve that reaches an asymptote at
antigen values of approximately 0.8 as Mf prevalence ap-
proaches 1. In other words, at high prevalence levels,
antigen tests estimate lower prevalence values than Mf
tests do. This phenomenon may be explained by the dif-
ference in sensitivity between these tests. Previous stud-
ies have shown the limitation in sensitivity of antigen
tests when detecting LF in patients [23, 30]. While Mas-
son et al. reported an 85.4% sensitivity of Og4C3 tests
compared to ICT [30], a study by Gass et al. discussed
the different sensitivities of these two antigen tests
against Mf results for LF [23]. This latter study reported
ICT and Og4C3 sensitivities of 76% and 87%, respect-
ively, against Mf tests [23], suggesting that their sensitiv-
ities are not too different. In fact, the resulting averaged
antigen sensitivity compared to Mf detection can be cal-
culated as 81.5%, which is highly comparable to predic-
tions from model B1. This may be a result of combining
both ICT and Og4C3 in our analyses. Thus, model B1
(and model A1) may be reflecting these sensitivity differ-
ences [23], by predicting antigen values of approximately
0.8 when Mf prevalence approaches 1 (Fig. 3).
Another illuminating characteristic of model B1 is that
it predicts both pre- and post-MDA curves converging
at high prevalence levels (Fig. 3). This could be a prod-
uct of the effect of MDA on Mf densities in individual
patients. The drugs used in an MDA are very effective at
dramatically reducing the density of Mf (especially at
low density levels) but less effective at permanently kill-
ing all adult worms in all individuals (especially in higher
density infections) [31]. As infected individuals will have
on average lower Mf densities in their blood at low levels
of Mf prevalence (and vice versa) [3], we would expect
MDA to potentially reduce patients’ Mf density to un-
detectable levels in such cases. As residual antigen from
adult worms would remain circulating in the blood
stream after MDA, the ratio between antigen and Mf
prevalence would be relatively higher at lower Mf
prevalence levels (< 0.3) as shown in model B1 (Fig. 3).
However, at higher levels of Mf prevalence, MDA may
not completely eliminate Mf densities, rendering Mf eas-
ier to detect. As a result, the ratio between antigen and
Mf prevalence will decrease as Mf prevalence increases,
resulting in similar ratios to pre-MDA surveys. Model
B1 (Fig. 3) shows this exact phenomenon, with the pre-
and post-MDA curves originally diverging, but conver-
ging as Mf increases, and it is thus applicable under both
conditions.
Model B1’s ability to predict the effect of MDA on dif-
ferent Mf densities, as well as reflecting sensitivity differ-
ences between tests, supports its use as a predictive
model for standardising prevalence values from hetero-
geneous surveys. However, model A4 deserves a closer
look. A previous study by Irvine et al. also tried to
describe the relationship between Mf and antigen test
results and how it would change after MDA implemen-
tation [26]. Initial parameters for their model were based
on historical data, while the predicted values for each of
the test types were focused on the same area, in an at-
tempt to evaluate the effectiveness of MDA implementa-
tion [26]. Irvine and colleagues provided evidence that a
correlation should exist to explain the relationship be-
tween tests. We used their model to reproduce this cor-
relation, depicted in Fig. 6. Here, we see that the
predicted antigen values converge as Mf prevalence ap-
proaches either 0 or 1 (Fig. 6).
Figure 6 suggests that, in our interpretation of Irvine
et al.’s model, antigen prevalence should always be
higher than Mf prevalence (Ag >Mf). This theoretical
approach leads to an asymptote only once these two
prevalences become equal (at Ag =Mf = 1), which is
similar to model A4. Both this theoretical model and
model A4 depict the antigen/Mf relationship under
post-MDA conditions, suggesting that perhaps under
certain circumstances MDA may create a diverging ef-
fect as shown in Fig. 2. However, this divergence can
also be a result of using a very small sample size of
post-MDA surveys in our study. Future research aimed
at exploring this possible post-MDA diverging relation-
ship should focus on obtaining values with high Mf
prevalence after MDA implementation, which can be
highly unlikely.
A number of other sources of error in our study may
be responsible for differences between the real relation-
ship between diagnostic tests and our proposed model.
Firstly, the method used to detect Mf (amount of blood
examined) was not consistent (nor consistently reported)
between surveys. Secondly, the sensitivity and specificity
of the ICT tests varied over the years, while the Og4C3
ELISA sensitivity and specificity vary according to
whether serum or dried blood spots were used [30].
Thirdly, each survey varied in precision due to the range
Berg Soto et al. Tropical Medicine and Health           (2018) 46:41 Page 8 of 11
in sample size and the age group of participants tested.
Additionally, the information on MDA is available only
at a population level, and we do not know whether indi-
viduals surveyed after MDA programs had actually par-
ticipated in the MDA or not. Despite these sources of
error between surveys, we were still able to detect a ro-
bust relationship between different diagnostic methods
to predict antigen values from Mf estimates. This rela-
tionship can be used to maximise the utility of sero-
logical surveys for spatial risk predictions as well as
improving LF transmission models by assisting in pre-
dictions of Mf prevalence at different transmission
stages, both before and after MDA.
By successfully combining varied survey estimates, we
were able to produce a more detailed depiction of LF
distribution in PNG, which shows a more complex pic-
ture than previously reported. While some previous as-
sessments claimed that PNG had one of the highest LF
prevalences in the world [13], one third of the surveys
considered in these study reported prevalence results
below 0.1 (Fig. 4). In fact, at least a fifth of these surveys
described prevalences below 0.01. As such, our study
provides a much clearer understanding of the real distri-
bution of LF across PNG.
Among these insights, we can see that the central high-
land districts of the country show low to no endemicity of
the disease—probably due to environmental factors affect-
ing vector distribution, such as altitude and temperature
[32]—while high prevalence of LF was located in the low-
land and coastal districts. This is particularly the case with
the North and South coasts and the Eastern islands. Fur-
ther survey efforts are needed in underserved areas, such as
West Sepik and inland East Sepik Provinces, some prov-
inces in the western highlands, the Southern Highlands
Province lowlands and the interior Gulf and Western
Provinces, including the Strickland river valley, as well as
southern New Britain island.
Conclusions
Our study confirms the predictive nature of the relation-
ship between antigen and Mf prevalence tests. The
models produced included the effect of MDA in this re-
lationship. Model B1 in particular showed a robust
goodness of fit and illuminated different aspects related
to the sensitivity of the tests and the effect of MDA at
different prevalence levels. The predictive nature of
model B1 allowed us to aggregate prevalence estimates
from assorted LF surveys to more accurately assess the
extent of the disease in PNG.
The prevalence distribution of LF across the country is
more complex than previously considered. While there
are certain provinces and districts showing high levels of
prevalence, many other regions of PNG have low to no
prevalence that may exclude them from the need to im-
plement MDA. With respect to the GPELF priorities for
PNG, our up-to-date risk map based on aggregated sur-
veys identifies high prevalence areas of the country that
the programme should prioritise for MDA implementa-
tion. Our risk map also identifies underserved survey
areas that the programme should further investigate to
reach a more detailed understanding of LF distribution
in PNG.
Underserved areas, however, may also reflect logistic-
ally challenging regions where additional surveys may be
Fig. 6 Graph showing the relationship between Mf and antigen prevalence values based on calculations using the model suggested by Irvine et
al. [26]. Our parameters’ assumptions were alpha = 0.50 (production rate of mf), m (0.2–4.0), kw (0.2–4.0) and phi (sensitivity, 0.97)
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unfeasible. Other alternatives to surveillance programs
may be required. Further spatial analyses are in progress
to develop predictive models based on environmental
transmission factors of the disease that can lead to the
identification of “hot spots” of potential high prevalence
in the country, as well as areas that are very unlikely to
be LF endemic, even in the absence of completed preva-
lence mapping. These spatial tools have been used in
previous studies [32, 33] suggesting that their implemen-
tation could help other countries in the Asia Pacific re-
gion face the logistic challenges of LF risk mapping and
eventual elimination.
The elimination of LF remains a global priority, espe-
cially in poor communities. Developing new tools and
approaches to accurately inform programmes, partners
and donors on possible best practices is essential. Our
study is a step towards this goal, in the hopes that this
information can help in the modelling efforts of LF
prevalence around the world and in the identification of
potential areas for future localised MDA implementation
in PNG.
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